This is a working overview of lyophilization, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
=== Proposed amalgamation === By early May 2026, several district and regional councils in Northland, Taranaki, the West Coast, Waikato, the Bay of Plenty, Wellington Wairarapa, Hawke's Bay and Southland Regions were discussing options to merge into unitary authorities as part of the Sixth National Government's policy of "simplifying" local government. On 5 May, the Local Government Minister Simon Watts and the RMA Reform Minister Chris Bishop issued local councils with a three-month timeframe to come up with amalgamation plans under the new "Head Start" approach. These amalgamation plans replaced the earlier proposed "combined territorial boards" and would be assessed by the newly-established Ministry for Cities, Environment, Regions and Transport (MCERT). The Government's 2026 amalgamation ultimatum received support from several local government leaders including Mayor of Nelson Nick Smith, Mayor of Southland Rob Scott, Mayor of Timaru Nigel Brown, Mayor of South Wairarapa Dame Fran Wilde, Mayor of Whangārei Ken Couper, Mayor of New Plymouth Max Brough, and Mayor of Invercargill Tom Campbell. By contrast, Mayor of Gore Ben Bell and Mayor of Rotorua Tania Tapsell expressed reservations about merger and the short time-frame. Meanwhile Mayor of Tasman Tim King preferred that the central government decide the local government model rather than delegating it to local councils.
===== Federal ===== The United States Congress has recognized that pseudoephedrine is used in the illegal manufacture of methamphetamine. In 2005, the Committee on Education and the Workforce heard testimony concerning education programs and state legislation designed to curb this illegal practice. Attempts to control the sale of the drug date back to 1986, when federal officials at the Drug Enforcement Administration (DEA) first drafted legislation, later proposed by Senator Bob Dole, that would have placed several chemicals used in the manufacture of illicit drugs under the Controlled Substances Act. The bill would have required each transaction involving pseudoephedrine to be reported to the government, and federal approval of all imports and exports. Fearing this would limit legitimate use of the drug, lobbyists from over-the-counter drug manufacturing associations sought to stop this legislation from moving forward and were successful in exempting from the regulations all chemicals that had been turned into a legal final product, such as Sudafed. Before the passage of the Combat Methamphetamine Epidemic Act of 2005, sales of the drug became increasingly regulated, as DEA regulators and pharmaceutical companies continued to fight for their respective positions. The DEA continued to make greater progress in its attempts to control pseudoephedrine as methamphetamine production skyrocketed, becoming a serious problem in the western United States.
The first symptom of CJD is usually rapidly progressive dementia, leading to memory loss, personality changes, and hallucinations. Myoclonus (jerky movements) typically occurs in 90% of cases, but may be absent at initial onset. Other frequently occurring features include anxiety, depression, paranoia, obsessive-compulsive symptoms, and psychosis. This is accompanied by physical problems such as speech impairment, balance and coordination dysfunction (ataxia), changes in gait, and rigid posture. In most people with CJD, these symptoms are accompanied by involuntary movements. Rarely, unusual symptoms like the alien limb phenomenon have been observed. The duration of the disease varies greatly, but sporadic (non-inherited) CJD can be fatal within months or even weeks. Most affected people die six months after initial symptoms appear, often of pneumonia due to impaired coughing reflexes. About 15% of people with CJD survive for two or more years. The symptoms of CJD are caused by the progressive death of the brain's nerve cells, which are associated with the build-up of abnormal prion proteins forming in the brain. When brain tissue from a person with CJD is examined under a microscope, many tiny holes can be seen where the nerve cells have died. Parts of the brain may resemble a sponge where the prions were infecting the areas of the brain.
However, the experimental chemistry of meitnerium has not received as much attention as that of the heavier elements from copernicium to livermorium. Lawrence Berkeley National Laboratory tried to synthesize 271Mt in 2002–2003 for a possible chemical investigation of meitnerium, as it was expected that it might be more stable than nearby isotopes due to having 162 neutrons, a magic number for deformed nuclei; its half-life was predicted to be a few seconds, long enough for a chemical investigation. However, no atoms of 271Mt were detected; this isotope of meitnerium is currently unknown. An experiment determining the chemical properties of a transactinide would need to compare a compound of that transactinide with analogous compounds of some of its lighter homologs: for example, in the chemical characterization of hassium, hassium tetroxide HsO4 was compared with the osmium analog, osmium tetroxide OsO4. In a preliminary step toward determining the chemical properties of meitnerium, the GSI attempted sublimation of rhodium(III) oxide Rh2O3 and rhodium(III) chloride RhCl3. However, macroscopic amounts of the oxide would not sublimate until 1000°C and the chloride would not until 780°C, and then only in the presence of carbon aerosol particles: these temperatures are far too high for such procedures to be used on meitnerium, as most of the current methods used for the investigation of the chemistry of superheavies do not work above 500°C.
=== Insulin glargine === Insulin glargine is a long-acting modified form of medical insulin used in the management of type 1 and type 2 diabetes. It is administered through subcutaneous injection. Its effects typically begin within an hour of injection. Common side effects include (hypoglycemia, issues at the injection site, itchiness, and weight gain. NPH insulin is generally preferred over insulin glargine during pregnancy. After injection, microcrystals gradually release insulin over a period of approximately 24 hours. This insulin works by facilitating the absorption of glucose by body tissues and reducing glucose production by the liver. Insulin glargine was patented, although the patent expired in most countries in 2014. It was approved for medical use in the United States in 2000. It is listed on the World Health Organization's List of Essential Medicines. In 2022, it ranked as the 28th most commonly prescribed medication in the United States, with more than 18 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product, Semglee (insulin glargine-yfgn), for the treatment of diabetes. Unbranded versions of insulin glargine and insulin glargine-yfgn are sold by Sanofi and Viatris.
Sources: en.wikipedia.org
The role of gastric acid in digestion was established in the 1820s and 1830s by William Beaumont on Alexis St. Martin, who, as a result of an accident, had a fistula (hole) in his stomach, which allowed Beaumont to observe the process of digestion and to extract gastric acid, verifying that acid played a crucial role in digestion.
Agilent ChemStation is a software package to control Agilent liquid chromatography, gas chromatography, and ultraviolet-visible spectroscopy systems such as the 1050, 1100 and 1200 Series HPLC system and the 8453 and 8454 single-beam diode array detector spectrophotometers. It is an evolution of the Hewlett-Packard ChemStation System. Two versions are available: one ("online") in connection with the modules of the HPLC chain is designed to control instruments and run experiments, and the other ("offline"), without a connection with the HPLC chain, is designed to analyze data. ChemStation is structured around a number of registers. Two of the more important registers are CHROMREG and CHROMRES, the chromatographic data registers. Other special registers exist for the UV-vis implementation of the software. ChemStation has a command line interpreter and can run macros. Those macros are files grouping a set of commands. These files possess a .mac extension. ChemStation can import analysis lists and export result files in XML by adding new lines to the ChemStation.ini configuration file. This is a feature to implement the connection with a Laboratory information management system (LIMS).
== Receptors == Most hormones initiate a cellular response by initially binding to either cell surface receptors or intracellular receptors. A cell may have several different receptors that recognize the same hormone but activate different signal transduction pathways, or a cell may have several different receptors that recognize different hormones and activate the same biochemical pathway. Receptors for most peptide as well as many eicosanoid hormones are embedded in the cell membrane as cell surface receptors, and the majority of these belong to the G protein-coupled receptor (GPCR) class of seven alpha helix transmembrane proteins. The interaction of hormone and receptor typically triggers a cascade of secondary effects within the cytoplasm of the cell, described as signal transduction, often involving phosphorylation or dephosphorylation of various other cytoplasmic proteins, changes in ion channel permeability, or increased concentrations of intracellular molecules that may act as secondary messengers (e.g., cyclic AMP). Some protein hormones also interact with intracellular receptors located in the cytoplasm or nucleus by an intracrine mechanism. For steroid or thyroid hormones, their receptors are located inside the cell within the cytoplasm of the target cell. These receptors belong to the nuclear receptor family of ligand-activated transcription factors. To bind their receptors, these hormones must first cross the cell membrane. They can do so because they are lipid-soluble.
==== Cannabis effectively outlawed, prescription drugs ==== With the passage of the Marihuana Tax Act of 1937, federal law reflected state law – by 1936, the non-medical use of cannabis had been banned in every state. That year, the first two arrests for tax non-payment under the act, for possession of a quarter-ounce (7g), and trafficking of four pounds (1.8 kg), resulted in sentences of nearly 18 months and four years respectively. The American Medical Association (AMA) had opposed the tax act on grounds that it unduly affected the medical use of cannabis. The AMA's legislative counsel, a physician, testified that the claims about cannabis addiction, violence and overdoses were not supported by evidence. Scholars have posited that the act was orchestrated by powerful business interests – Andrew Mellon, Randolph Hearst, and the Du Pont family – to head off cheap competition to pulp and timber and plastics from the hemp industry. After the act, cannabis research and medical testing became rare. In 1939, New York City Mayor Fiorello LaGuardia, an opponent of the Marihuana Tax Act, formed the LaGuardia Committee to conduct the first US in-depth study of cannabis use. The report, produced by the New York Academy of Medicine and released in 1944, systematically contradicted government claims, finding that cannabis is not physically addictive, and its use does not lead to using other drugs or to crime. The FBN's Anslinger branded the study "unscientific", denounced all involved, and disrupted other cannabis studies at the time.
Sources: en.wikipedia.org
Insulated shipping containers are part of a comprehensive cold chain which controls and documents the temperature of a product through its entire distribution cycle. The containers may be used with a refrigerant or coolant such as:
=== Toxicity of pentavalent arsenicals === Due to its similar structure and properties, pentavalent arsenic metabolites are capable of replacing the phosphate group of many metabolic pathways. The replacement of phosphate by arsenate is initiated when arsenate reacts with glucose and gluconate in vitro. This reaction generates glucose-6-arsenate and 6-arsenogluconate, which act as analogs for glucose-6-phosphate and 6-phosphogluconate. At the substrate level, during glycolysis, glucose-6-arsenate binds as a substrate to glucose-6-phosphate dehydrogenase, and also inhibits hexokinase through negative feedback. Unlike the importance of phosphate in glycolysis, the presence of arsenate restricts the generation of ATP by forming an unstable anhydride product, through the reaction with D-glyceraldehyde-3-phosphate. The anhydride 1-arsenato-3-phospho-D-glycerate generated readily hydrolyzes due to the longer bond length of As-O compared to P-O. At the mitochondrial level, arsenate uncouples the synthesis of ATP by binding to ADP in the presence of succinate, thus forming an unstable compound that ultimately results in a decrease of ATP net gain. Arsenite (III) metabolites, on the other hand, have limited effect on ATP production in red blood cells.
Administratively, Le Havre is a commune in the Normandy region in the west of the department of Seine-Maritime. The urban area of Le Havre corresponds roughly to the territory of the Agglomeration community of Le Havre (CODAH) which includes 17 communes and 250,000 people. It occupies the south-western tip of the natural region of Pays de Caux where it is the largest city. Le Havre is sandwiched between the coast of the Channel from south-west to north-west and the estuary of the Seine to the south.
Cycling extract is a cell-free system derived from Xenopus eggs that autonomously undergoes repeated S phase and M phase cycles. It is prepared by artificially inducing intracellular responses that mimic fertilization, typically through calcium ionophore treatment or electrical stimulation of unfertilized eggs, followed by mechanical crushing of the eggs. This extract has been instrumental in elucidating fundamental mechanisms of cell cycle regulation. For example, it revealed that entry into M phase depends on the translation of cyclin B, which in turn activates maturation promoting factor (MPF). Cycling extracts are primarily used to study the regulation of cell cycle progression.
== Etymology == The name derives from the Ancient Greek word πολύς (polus, meaning "many, much") and the word 'phenol' which refers to a chemical structure formed by attachment of an aromatic benzenoid (phenyl) ring to a hydroxyl (-OH) group (hence the -ol suffix). The term "polyphenol" has been in use at least since 1894.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.